重组人血管内皮抑制素 (先声药业)(Recombinant Human Endostatin (Simcere)) - 药物靶点：VEGFR_在研适应症：非小细胞肺癌，恶性腹水，恶性胸腔积液_专利_临床

概要

基本信息

药物类型

重组蛋白

别名

Endostar、Endu、rh-endostatin

+ [2]

靶点

VEGFR

作用方式

拮抗剂

作用机制

VEGFR拮抗剂(血管内皮细胞生长因子受体拮抗剂)

治疗领域

肿瘤呼吸系统疾病其他疾病

在研适应症

非小细胞肺癌恶性腹水恶性胸腔积液

非在研适应症

晚期结直肠腺癌晚期肺腺癌晚期非小细胞肺癌+ [7]

原研机构

先聲藥業集團有限公司

在研机构

山东先声生物制药有限公司

非在研机构

江苏先声药业有限公司

最高研发阶段批准上市

首次获批日期

中国 (2005-09-12),

非小细胞肺癌

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 720094457

关联

100

项与重组人血管内皮抑制素 (先声药业) 相关的临床试验

NCT06618391

/ Not yet recruiting临床2期IIT

Envafolimab and Recombinant Human Endostatin and Recombinant Human Adenovirus Type 5 Intratumor Local Injection Combined With Systemic Therapy in Patients With Advanced NSCLC :a Prospective, Exploratory Phase II Clinical Study Tudy

This study is a prospective, exploratory Phase II clinical study aimed at evaluating the safety and efficacy of Envafolimab and recombinant human endostatin and Recombinant Human Adenovirus Type 5 Intratumor local injection combined with systemic therapy in patients with locally advanced or advanced non-small cell lung cancer(NSCLC).

开始日期2024-10-08

申办/合作机构

河南省肿瘤医院

NCT06617936

/ Recruiting临床2期IIT

Tislelizumab Combined With Recombinant Human Endostatin Injection Plus Chemotherapy in Unresectable Stage III NSCLC: a Prospective, Single-arm, Multicenter Phase II Clinical Study

This is a prospective, single-arm, multicenter, phase II clinical study designed to evaluate the initial efficacy and safety of patients receiving Tislelizumab in combination with recombinant human endostatin injection plus chemotherapy for stage III unresectable non-small cell lung cancer. To evaluate the surgical conversion rate of tirellizumab combined with recombinant human endostatin injection and chemotherapy induction therapy in patients with initially unresectable stage III non-small cell lung cancer.

开始日期2024-08-27

申办/合作机构

上海大众卫生投资有限公司

NCT06562673

/ Not yet recruiting临床1/2期IIT

Efficacy and Safety of Intra-arterial Cisplatin Plus Anti-angiogenesis Inhibitor Rh-endostatin (Endostar) Combined With Systematic Chemotherapy in Osteosarcoma

The goal of this clinical trial is to learn the efficacy and safety of intra-arterial cisplatin plus anti-angiogenesis inhibitor rh-endostatin (Endostar) combined with systematic chemotherapy in osteosarcoma. The main questions it aims to answer are:
* Is it safe when rh-endostatin and cisplatin are administered intra-arterially?
* Does intra-arterial cisplatin plus rh-endostatin increase the rate of tumor necrosis compared with traditional treatment?
Researchers will treat newly diagnosed osteosarcoma patients with systematic treatment and local treatment.
For systematic treatment, regular high-dose methotrexate and adriamycin will be administered intravenously.
For local treatment, rh-endostatin was administered intra-arterially with dosage of 150 mg for a 6-h continuous infusion; then cisplatin was administered intra-arterially at 120 mg/m2 as a 6-h continuous infusion.
Local treatment is conducted by insertion of a catheter percutaneously using the Seldinger technique through the brachial or femoral artery under local anesthesia.
Participants will:
• Receive local combined with systematic treatment once every 2-3 weeks for 2-4 cycles before surgery.

开始日期2024-08-20

申办/合作机构-

100 项与重组人血管内皮抑制素 (先声药业) 相关的临床结果

登录后查看更多信息

100 项与重组人血管内皮抑制素 (先声药业) 相关的转化医学

登录后查看更多信息

100 项与重组人血管内皮抑制素 (先声药业) 相关的专利（医药）

登录后查看更多信息

529

项与重组人血管内皮抑制素 (先声药业) 相关的文献（医药）

2025-03-01·Supportive Care in Cancer

Prognostic value of prognostic nutritional index in patients with nasopharyngeal carcinoma treated with endostar and concurrent chemoradiotherapy

Article

作者: Huang, Qiulin ; Wang, RenSheng ; Bie, Jun ; Song, JunMei ; Liu, Ting ; Lv, YuQing ; Wen, YaJing

PURPOSEThis study aimed to evaluate the prognostic value of the pre-treatment prognostic nutritional index (PNI) in patients with locally advanced nasopharyngeal carcinoma (LANPC) treated with endostar combined with concurrent chemoradiotherapy (ECCRT).METHODSClinical data from 92 patients with LANPC who underwent ECCRT between May 2015 and December 2020 were retrospectively analyzed. The PNI was calculated using peripheral blood samples taken 1 week before treatment. The optimal cut-off value for PNI was determined via receiver operating characteristic (ROC) curve analysis based on overall survival (OS). Patients were categorized into high PNI and low PNI groups. The Kaplan-Meier method assessed the impact of PNI on survival, while univariate and multivariate Cox regression analyses identified independent risk factors affecting patient survival.RESULTSThe optimal cut-off value of PNI was 50.05. The 3-year OS, progression-free survival (PFS), distant metastasis-free survival (DMFS), and local recurrence-free survival (LRRFS) rates were 91.07% vs. 75.00% (P = 0.002), 83.93% vs. 66.67% (P = 0.015), 89.29% vs. 69.44% (P = 0.004), and 94.64% vs. 91.67% (P = 0.668) in the high PNI and low PNI groups, respectively. A low PNI was associated with shorter OS (HR = 3.592, P = 0.004), PFS (HR = 2.890, P = 0.017), and DMFS (HR = 3.826, P = 0.008). Multivariate analysis revealed that PNI was an independent prognostic factor for OS, PFS, and DMFS.CONCLUSIONSThe PNI may serve as a valuable prognostic predictor for patients with LANPC receiving ECCRT, aiding clinicians in selectively providing multimodal interventions to optimize survival outcomes.

2025-03-01·Environmental Toxicology

RETRACTED: Poly (lactic‐co‐glycolic acid)‐encapsulated Endostar‐loaded calcium phosphate cement as anti‐tumor bone cement for the treatment of bone metastasis in lung cancer

Article

作者: Zhang, Kaixian ; Tian, Cong ; Tian, QingHua ; Lu, YingYing ; Wu, ChunGen ; Yan, BiCong

AbstractLung cancer is one of the most common malignant tumors in the world. In approximately 30%–40% of lung cancer patients, bone metastases ensues with osteolytic destruction. Worse still, intractable pain, pathological fracture, and nerve compression caused by bone metastases are currently the bottleneck of research, diagnosis, and treatment of lung cancer. Therefore, the present study aims at investigating the effectiveness of a new composite material made of calcium phosphate cement (CPC) and Endostar on repairing bone defects in vitro and in vivo. As indicated in results, the mechanical properties of CPC+Endostar and CPC+PLGA+Endostar do not differ from those of pure CPC. The PLGA‐embedded Endostar slow‐release microspheres were designed and prepared, and were combined with CPC. Poly (lactic‐co‐glycolic acid (PLGA) is a biodegradable polymer material in vivo, so the effect on its mechanical properties is negligible. CPC+Endostar and CPC+PLGA+Endostar have been proved to inhibit cell proliferation, promote apoptosis and block cell cycle in G2 phase; the expression levels of osteoclast‐related genes CXCL2, TGF‐β1, IGF‐1, IL‐6, and RANKL were significantly decreased while osteogenic ability and alkaline phosphatase activity observably enhanced. In vivo studies have revealed that the expression levels of TRAP, RANKL, and Caspase3 in CPC+PLGA+ENDO‐treated tumor tissues after 3 weeks were higher than those in other groups with the prolongation of animal treatment time, while the expression levels of OPN and BCL2 were lower than those in other groups. In hematoxylin and eosin and TUNEL staining, 3 weeks of CPC+PLGA+ENDO‐treatment yielded higher tissue necrosis and apoptosis than other groups; computed tomography and magnetic resonance imaging results showed the posterior edge bone damage reduced as a result of the CPC+PLGA+ENDO grafting in vertebral pedicle. Overall, the feasibility and reliability of CPC‐loaded Endostar in the treatment of bone metastasis in lung cancer were investigated in this study, so as to promote the basic research and treatment of bone metastasis in lung cancer and other malignant tumors.

2025-02-07·Medicine

Study on PD-1 inhibitor combined with recombinant human endostatin and chemotherapy followed by IMRT in the treatment of advanced NSCLC

Article

作者: Qi, ZhengJun ; Liao, GuangHui ; Dong, ChangFen ; Zhao, LiLi ; Lu, FangYang ; Su, XiaLu ; Sun, Yi ; Ma, FaQiang

Although chemotherapy, targeted therapy, and antiangiogenic drugs have become the cornerstones of treatment for advanced non-small-cell carcinoma (NSCLC) in clinical practice, the emergence of immune checkpoint inhibitors (such as PD-1 inhibitors) in recent years has also provided new options for the treatment of NSCLC. To explore whether PD-1 inhibitors combined with recombinant human endostatin and chemotherapy followed by IMRT have a certain curative effect in the treatment of advanced NSCLC. We retrospectively analyzed 47 patients with stage IIIB, IIIC, and IV NSCLC admitted to our hospital from August 2022 to June 2023. According to the treatment method, the patients were divided into an observation group (24 cases) and a control group (23 cases). The control group only received recombinant human endostatin 105 g and chemotherapy followed by IMRT; the observation group received domestic PD-1 inhibitors, 200 mg, and chemotherapy followed by IMRT on the basis of the treatment plan of the control group. After treatment, the objective response rate (ORR), disease control rate, overall survival, progression-free survival (PFS), duration of response, and incidence of adverse reactions were compared. After treatment, the ORR and disease control rate of the observation group were higher than those of the control group; compared with the control group, the PFS, overall survival, and duration of response period of the observation group were longer (P < .05); the incidence of adverse reactions in the observation group was significantly lower than that in the control group (P < .05). After chemotherapy, the CD3+ and CD4+ index of the observation group was significantly increased, the CD3+ CD8+ was slightly lower than that of the control group, without statistical significance, and the ratio of CD4/CD8 was higher than that of the control group, and the interleukin-2 index was significantly better than that of the routine group, P < .05. PD-1 inhibitor combined with recombinant human endostatin and chemotherapy followed by IMRT in the treatment of advanced NSCLC can significantly improve the ORR and prolong the PFS of patients, and the adverse reactions are controllable. The results of our study may provide help for the treatment strategies of patients with refractory advanced NSCLC, and are worthy of promotion and use.

54

项与重组人血管内皮抑制素 (先声药业) 相关的新闻（医药）

2025-02-26

·先声药业

先声再明CDH6 ADC完成Ⅰ期临床首例患者用药

2025年2月26日，先声药业集团（2096.HK）旗下抗肿瘤创新药公司先声再明宣布，其自主研发的CDH6抗体偶联药物（ADC）SIM0505已启动针对晚期实体瘤的Ⅰ期临床研究，并于复旦大学附属肿瘤医院完成首例患者用药。该Ⅰ期临床研究由复旦大学附属肿瘤医院吴小华教授牵头，旨在评价SIM0505在晚期实体瘤受试者中的安全性、药代动力学和抗肿瘤活性。 CDH6（钙粘蛋白-6或K-钙粘蛋白）是一种单次跨膜蛋白，参与细胞间粘附、器官发育和上皮间质转化。CDH6在正常组织中表达极低，而在多种肿瘤中高表达，有望成为晚期肿瘤治疗的重要靶点。 SIM0505为先声再明自有技术平台开发的ADC项目，已在中美两国获准进入临床研究。该分子结合了CDH6抗体分子的肿瘤特异靶向性和喜树碱类毒素分子的高杀伤性，对卵巢癌、肾癌等恶性肿瘤具有治疗潜力。先声再明是先声药业集团旗下专注于抗肿瘤创新药研发、生产和商业化的生物医药公司，2023年起独立运营，致力于以突破性治疗手段, 解决中国乃至全球肿瘤领域巨大的未满足临床需求。再明着力打造高价值创新管线，已上市产品组合包含科赛拉®、恩维达®、恩度®、恩立妥®4款创新药。再明与全球合作伙伴的协同创新，为临床提供更有效的治疗手段，让更多肿瘤患者再现生机与光明。媒体联络：pr@zaiming.com 编辑 | 李逸玲审校 | 陈瑶审核 | 高兴元胡爽

抗体药物偶联物临床1期临床2期

2025-01-14

·艾伯维abbvie

艾伯维宣布与先声再明合作开发治疗多发性骨髓瘤的新型三特异性抗体候选药物

1月 13 日，艾伯维与先声药业集团有限公司子公司先声再明宣布，双方就在研候选药物SIM0500达成许可选择协议。SIM0500目前正在中美两国开展针对复发或难治性多发性骨髓瘤(MM)的临床1期研究。 SIM0500是一种靶向GPRC5D、BCMA和 CD3的人源化三特异性抗体，由先声再明使用其 T 细胞衔接器多特异性抗体技术平台独立开发。该分子结合了低亲和力而高靶向激活的CD3抗体，以及抗G蛋白偶联受体C家族5组成员D（GPRC5D）和抗B细胞成熟抗原（BCMA）的两种抗肿瘤相关抗体。SIM0500通过多种抗肿瘤机制，表现出了针对MM细胞的强大T细胞毒性效应。 Mariana Cota Stirner博士艾伯维副总裁、血液肿瘤治疗领域负责人作为血液肿瘤领域的领导者，艾伯维致力于通过不懈的研发和合作，推进针对多发性骨髓瘤等复杂肿瘤的创新疗法。我们期待与先声再明合作，推进这种新型的三特异性抗体的研发。它有可能帮助解决多发性骨髓瘤患者尚未满足的重大临床需求。唐仁宏博士先声再明首席执行官 SIM0500是通过先声再明专有的T细胞接触器平台开发的。我们很高兴能与艾伯维合作开发这种新的候选药物，并期待共同推进 SIM0500的临床开发进程。先声再明将获得艾伯维的首付款，以及最高10.55亿美金的选择性权益付款和里程碑付款。先声再明将额外获得基于该产品在大中华区以外地区净销售额的分级特许权使用费。艾伯维有权获得大中华区净销售额的分级特许权使用费。关于艾伯维肿瘤学领域在艾伯维，我们致力于改变难以治疗的肿瘤患者的护理标准。我们正在推进针对血液肿瘤和实体肿瘤中各种肿瘤类型的动态研究疗法产品线。我们正在专注于开发能够阻碍肿瘤细胞繁殖或消除肿瘤细胞的靶向药物。我们通过各种靶向治疗模式和生物学干预来实现这一目标，包括小分子疗法、抗体药物偶联物（ADC）、基于免疫肿瘤学的疗法、多特异性抗体和原位CAR-T平台。我们敬业且经验丰富的团队与创新合作伙伴联手，加快潜在突破性药物的交付。如今，我们广泛的肿瘤学产品组合包括针对各种血液和实体肿瘤的已获批准和在研的治疗方法。我们正在针对世界上一些最广泛和最令人衰弱的肿瘤的多项临床试验中评估20多种在研药物。在我们努力对人们的生活产生显著影响的同时，我们致力于探索解决方案，帮助患者获得我们的抗肿瘤药物。欲了解更多信息，请访问 http://www.abbvie.com/oncology。关于先声再明先声再明是先声药业集团旗下专注于抗肿瘤创新药研发、生产和商业化的生物医药公司，2023年起独立运营，致力于以突破性治疗手段, 解决中国乃至全球肿瘤领域巨大的未满足临床需求。再明着力打造高价值创新管线，已上市产品组合包含科赛拉®、恩维达®、恩度®、恩立妥®4款创新药。再明与全球合作伙伴的协同创新，为临床提供更有效的治疗手段，让更多肿瘤患者再现生机与光明。上下滑动查看更多信息艾伯维前瞻性陈述本新闻稿中的某些陈述可能为前瞻性陈述。“相信”、“期望”、“预期”、“计划”和类似表达通常被视为前瞻性陈述。艾伯维提醒，这些前瞻性陈述存在风险和不确定性，可能导致实际结果与前瞻性陈述中指出的结果有重大差异。这些风险和不确定性包括但不限于：知识产权的挑战；来自其他产品的竞争；研发过程中固有的困难；不利的诉讼和政府行为；适用于我们行业的法律法规的变化。关于可能影响艾伯维运营的经济、竞争、政府、技术和其他因素的额外信息，请参见艾伯维提交给美国证券交易委员会的2023年度报告的10-K表格的第1A项“风险因素”，以及随后更新的季度报告的10-Q表格。除非法律要求，艾伯维不承担因后续事件或发展而公开发布对前瞻性陈述的任何修订的义务。

免疫疗法细胞疗法抗体药物偶联物临床1期引进/卖出

2025-01-13

·PRNewswire

Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma

SHANGHAI and NORTH CHICAGO, Ill., Jan. 13, 2025 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currently in Phase 1 clinical trials in patients with relapsed or refractory multiple myeloma (MM), in both China and the U.S. Continue Reading Cooperation of Simcere Zaiming and Abbvie SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3, developed independently by Simcere Zaiming using their T-cell engager polyspecific antibody technology platform. This molecule features a low affinity/high target-activating CD3 engaging arm and binding sites for the two tumor antigens: G-Protein-coupled receptor class 5 member D (GPRC5D) and B-cell maturation antigen (BCMA). SIM0500 has shown strong T cell cytotoxicity against multiple myeloma (MM) cells by leveraging a combination of various antitumor effects. "As a leader in hematologic malignancies, AbbVie is committed to advancing innovative treatments for complex cancers like multiple myeloma through our relentless R&D efforts and collaborations," said Mariana Cota Stirner, M.D., Ph.D., vice president, therapeutic area head for hematology, AbbVie. "We look forward to partnering with Simcere Zaiming, to advance this novel trispecific antibody, which has the potential to help address significant unmet medical needs for people living with multiple myeloma" "SIM0500 is developed via Simcere Zaiming's proprietary T-cell engager platform," said Renhong Tang, PhD, CEO of Simcere Zaiming. "We are excited to partner with AbbVie on this novel drug candidate and look forward to working together to advance the clinical development of SIM0500. " Simcere Zaiming will receive an upfront payment from AbbVie and is eligible to receive option fees and milestone payments of up to $1.055B, as well as tiered royalties on net sales outside of the Greater China territory. AbbVie is eligible to receive tiered royalties on net sales in the Greater China territory About AbbVie in Oncology At AbbVie, we are committed to transforming standards of care for patients living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and in situ CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines. Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood and solid tumors. We are evaluating more than 20 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit . About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. AbbVie strives to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in AbbVie's Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at . Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube. About Simcere Zaiming Simcere Zaiming is an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096, "Simcere"). Founded in 2023, Simcere Zaiming dedicated to developing groundbreaking therapies to meet the unmet clinical needs of cancer patients globally. With a robust and innovative R&D pipeline featuring distinct clinical assets, Simcere Zaiming has successfully launched several innovative products in China, including COSELA®, Enweida®, Endostar®, and Enlituo®. The company is determined to deliver potentially transformative treatment options to cancer patients worldwide through its internal R&D, manufacturing, and commercialization capabilities, complemented by strategic collaborations with leading partners. SOURCE Simcere Zaiming WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

引进/卖出临床1期抗体药物偶联物

100 项与重组人血管内皮抑制素 (先声药业) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L01	DB06423

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
非小细胞肺癌	中国	山东先声生物制药有限公司	2005-09-12

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
恶性腹水	临床3期	中国	山东先声生物制药有限公司	2021-07-21
恶性胸腔积液	临床3期	中国	山东先声生物制药有限公司	2021-07-21
局部晚期非小细胞肺癌	药物发现	中国	江苏先声药业有限公司	2018-08-01
晚期结直肠腺癌	药物发现	中国	江苏先声药业有限公司	2018-07-01
晚期肺腺癌	药物发现	中国	江苏先声药业有限公司	2012-03-01
脑转移瘤	药物发现	中国	江苏先声药业有限公司	2011-06-01
T细胞淋巴瘤	药物发现	中国	江苏先声药业有限公司	2011-06-01
食管癌	药物发现	中国	江苏先声药业有限公司	2011-05-01
局部晚期黑色素瘤	药物发现	中国	江苏先声药业有限公司	2008-08-01
转移性黑色素瘤	药物发现	中国	江苏先声药业有限公司	2008-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


WCLC2024 人工标引	临床2期	非小细胞肺癌一线 driver gene-negative	29	EnvafolimabRh-endostatin	(襯範鹽蓋壓餘觸鑰觸艱) = 餘鹹壓範簾餘積積壓糧鹹選簾窪積艱簾遞顧憲 (顧壓獵築艱選製遞簾築, 76.8 ~ 109.4) 更多	积极	2024-09-09
ESMO_ELCC 12024 \| ESMO_ELCC 22024 人工标引	临床2期	非小细胞肺癌一线	29	Envafolimab+Rh-endostatin+platinum-based dual-agent chemotherapy	(網淵蓋築範齋餘遞範積) = 艱糧鏇鬱願醖選範範製壓顧鬱鏇網膚鏇窪憲網 (蓋窪窪窪鑰網壓積艱鏇, 54.3 ~ 85.3) 更多	积极	2024-03-20
ESMO_ASIA2023	临床2期	局部晚期食管鳞状细胞癌	90	Endostar plus concurrent chemoradiotherapy (CCRT)	憲鏇糧網醖壓選淵襯鏇(鹽憲遞製選鬱選齋鏇餘) = 齋選築積鑰夢鏇艱醖淵網憲築淵廠製顧襯顧蓋 (網願繭鹹壓鏇選蓋餘獵 ) 更多	积极	2023-12-02
				Concurrent chemoradiotherapy (CCRT)	(鹽築範鑰淵構遞餘淵衊) = 鹽鏇淵願齋艱顧淵醖繭鏇夢觸願鹹獵獵顧壓網 (獵憲製鹽餘憲選淵膚鬱 ) 更多
ESMO 12023 \| ESMO 22023 人工标引	临床2期	局部晚期食管鳞状细胞癌	92	Endostar+concurrent chemoradiotherapy	(憲顧遞艱製網築構鬱壓) = 艱齋膚衊衊艱鹽繭範構壓鹹遞簾鏇鬱簾鹹餘壓 (齋淵壓遞願範鏇鏇壓鏇 ) 更多	积极	2023-10-23
				Concurrent chemoradiotherapy	(憲顧遞艱製網築構鬱壓) = 鏇製餘鏇鹹鑰築構鏇襯壓鹹遞簾鏇鬱簾鹹餘壓 (齋淵壓遞願範鏇鏇壓鏇 ) 更多
ESMO_GCC2023	N/A	局部晚期宫颈癌	41	Endostar combined with chemoradiotherapy	鹹鬱艱網衊膚顧選蓋衊(襯範願餘製憲衊選醖壓) = 醖壓簾襯製糧淵夢夢醖夢艱願齋構築觸鏇獵膚 (糧蓋鑰糧襯淵遞積鏇糧 ) 更多	-	2023-02-23
				Chemoradiotherapy	鹹鬱艱網衊膚顧選蓋衊(襯範願餘製憲衊選醖壓) = 醖壓觸簾遞顧廠窪齋鏇夢艱願齋構築觸鏇獵膚 (糧蓋鑰糧襯淵遞積鏇糧 ) 更多
ESMO2022	N/A	晚期非小细胞肺癌一线	100	PD-1 inhibitors + Rh-endostatin + chemotherapy	(願顧糧鑰糧鹹願簾窪繭) = 糧願願網糧範膚顧衊製顧簾夢淵廠壓窪淵膚網 (糧網淵獵膚醖襯衊醖鬱 ) 更多	积极	2022-09-10
				Rh-endostatin + chemotherapy	(願顧糧鑰糧鹹願簾窪繭) = 繭鬱糧壓範範願繭鹽憲顧簾夢淵廠壓窪淵膚網 (糧網淵獵膚醖襯衊醖鬱 ) 更多
WCLC2022	N/A	晚期非小细胞肺癌	27	Endostar + Camrelizumab + Chemotherapy	(壓顧顧選窪製獵餘鹽鬱) = 鬱製簾襯襯構構膚窪構鑰簾衊膚鹹選齋鏇構觸 (顧鏇醖餘製鏇鹹窪鏇廠 ) 更多	-	2022-08-06
NCT03797625 (Pubmed \| Oncologist) 人工标引	临床2期	晚期食管鳞状细胞癌二线	50	Irinotecan+Cisplatin+Rh-Endostatin	(鏇範廠簾齋繭廠繭簾夢) = 鑰衊鹹遞齋構廠築構淵衊夢積範鏇積網鬱鏇糧 (蓋願顧憲簾構鬱壓艱醖, 3.19 ~ 5.49) 更多	积极	2022-04-05
CSCO2021	N/A	非鳞状非小细胞肺癌	24	恩度+化疗联合PD-1单抗治疗组	(廠獵壓範遞淵衊鹽艱廠) = 廠觸餘醖窪顧衊廠鏇憲壓廠顧獵衊鹽範簾齋憲 (鬱鹽網窪構獵鬱遞網衊 ) 更多	-	2021-09-25
				恩度+化疗组	(廠獵壓範遞淵衊鹽艱廠) = 繭鏇簾淵構壓觸繭顧鏇壓廠顧獵衊鹽範簾齋憲 (鬱鹽網窪構獵鬱遞網衊 ) 更多
CSCO2021	N/A	-	60	吉非替尼	(淵衊膚窪簾憲鬱簾鑰艱) = 顧網網簾膚製簾鑰壓選簾夢廠襯襯廠選餘網齋 (淵獵網壓壓鹹衊遞積鹹 )	-	2021-09-25
				吉非替尼联合重组人血管内皮抑制素注射液	(淵衊膚窪簾憲鬱簾鑰艱) = 鹹選鬱遞壓選膚窪衊範簾夢廠襯襯廠選餘網齋 (淵獵網壓壓鹹衊遞積鹹 )